Cite
HARVARD Citation
Hu, Y. et al. (2021). The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada. Journal of medical economics. pp. 150-161. [Online].